



Medical Coverage Policy

Effective Date4/1/2024

Next Review Date1/15/2025

Coverage Policy Number..... 0048

Breast Implant Removal

Table of Contents

Overview	2
Coverage Policy.....	2
General Background	3
Medicare Coverage Determinations	9
Coding Information.....	9
References	10
Revision Details	16

Related Coverage Resources

- [Breast Imaging Guidelines](#)
- [Breast Reconstruction Following Mastectomy or Lumpectomy](#)
- [Treatment of Gender Dysphoria](#)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health

benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This Coverage Policy addresses removal of silicone gel-filled or saline-filled breast implants and subsequent surgical implantation of a new U.S. Food and Drug Administration (FDA)-approved breast implant.

Coverage Policy

Coverage for breast implant removal varies across plans and may be governed by federal and/or state mandates. Please refer to the federal mandate on breast reconstruction and the customer's benefit plan document for coverage details.

Removal of either a saline-filled OR silicone gel-filled breast implant when associated with breast reconstruction following mastectomy or lumpectomy is considered medically necessary for ANY indication, including for the purpose of producing a symmetrical appearance of the nondiseased breast.

The removal of a silicone gel-filled breast implant with or without capsulectomy is considered medically necessary when rupture of the implant and/or extrusion of the implant contents have been confirmed on imaging studies (i.e., mammography, ultrasound, or magnetic resonance imaging [MRI]).

The removal of EITHER a silicone gel-filled OR saline-filled breast implant, with or without capsulectomy, is considered medically necessary for at least ONE of the following indications:

- **The implant is interfering with EITHER of the following:**
 - diagnostic evaluation of a suspected breast cancer
 - adequate treatment of known breast cancer (e.g., obstructing radiation therapy)
- **ANY of the following:**
 - acute, persistent or recurrent local or systemic infection secondary to a breast implant when there is failure, contraindication, or intolerance to medical management, including antibiotics
 - exposure of a breast implant
 - Baker Stage IV capsular contracture
 - tissue necrosis secondary to the implant
 - diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)
 - current use of Allergan BIOCELL textured breast implants and tissue expanders
 - diagnosis of breast implant-associated squamous cell carcinoma (BIA-SCC)

Removal of an intact silicone gel-filled breast implant when performed solely for suspected autoimmune disease or connective tissue disease or breast cancer prevention is considered not medically necessary.

The following are considered not medically necessary and/or cosmetic unless associated with breast reconstruction following mastectomy or lumpectomy:

- removal of a ruptured saline-filled implant in the absence of one of the indications listed above
- removal of any type of breast implant when performed for ANY of the following:
 - solely to treat psychological symptomatology or psychosocial complaints
 - solely to improve appearance
 - solely because of shifting or migration of the implant
 - removal of the implant in the opposite/contralateral breast, unless criteria are otherwise met for that breast implant
 - for any other indication not otherwise mentioned above as covered
- replacement of an implant following removal

Following removal of a breast implant, the subsequent surgical implantation of a new U.S. Food and Drug Administration (FDA)-approved breast implant is considered medically necessary for EITHER of the following:

- breast reconstruction of a diseased or affected breast following mastectomy or lumpectomy
- creation of a symmetrical appearance in the contralateral/nondiseased breast following mastectomy or lumpectomy in the opposite breast

General Background

Breast implants vary in shell surface (e.g., smooth versus textured), shape (e.g., round or shaped), profile (i.e., how far it protrudes), volume (i.e., size) and shell thickness. The primary components of most breast implants are a shell, otherwise known as the envelope or lumen, filler (e.g., saline, silicone gel or alternative) and a patch to cover the manufacturing hole.

While most breast implants are single lumen (i.e., shell only), some breast implants are double lumen (i.e., one shell inside the other). Some breast implants are manufactured with a fixed volume or filler; some are filled during surgery; and some allow for adjustments of the filler volume after implantation.

Breast implants are typically inserted under local or general anesthesia in an outpatient setting. If the procedure is done for cosmetic reasons, the incision is most commonly made along the lower edge of the areola, in the axilla or in the inframammary fold. For postmastectomy reconstruction, the surgical incision is used and the implant is placed either deep in the breast on the pectoral fascia (i.e., submammary) or beneath the pectoralis major.

Surgical complications associated with breast implantation are similar to those encountered with other breast surgeries: infection, bleeding, change in nipple sensation (e.g., hypersensitivity or hyposensitivity), malposition, delayed healing, and anesthetic accidents.

Although breast implants may be inserted for either reconstructive or cosmetic reasons, clinically significant post-implant complications may occur, necessitating removal of the implants. Local complications associated with breast implants include: capsular contracture, acute or persistent infection, silicone implant extrusion, tissue necrosis and silicone implant rupture. These conditions, when they become clinically significant, may require removal of the implant. Additionally, the presence of an implant may interfere with the diagnosis or treatment of breast cancer. Infections that may occur in or around an implant include wound infections, as well as infections within a

capsular contracture or as a result of a ruptured implant. Toxic shock syndrome is a rare complication with multiple systemic symptoms but usually does not have inflammation or purulence at the surgical site (Lalani, et al., 2022; Kim et al., 2021). Removal of the implant may be necessary when the infection does not respond to antibiotics. Unstable or weakened tissue and/or interruption in wound healing may result in the implant breaking through the skin (exposing it) or extrusion. Necrotic tissue may form around the implant, requiring implant removal. Silicone gel-filled implant rupture may cause the contents to leak into the surrounding tissues.

U.S. Food and Drug Administration (FDA)

In the FDA labeling for approved breast implants, Mentor™ Corp., Santa Barbara, CA; Allergan™ Corp. (formerly Inamed™), Irvine, CA; Ideal Implant®, Inc., Dallas, TX; and Sientra™, Inc., Santa Barbara, CA are listed as manufacturers of silicone and saline breast implants (FDA, 2022).

FDA-approved saline-filled implants:

- Allergan (formerly Inamed) Natrelle Saline Breast Implants (P020056 and P990074)
 - In July 2019, Allergan voluntarily recalled Natrelle BIOCELL textured breast implants and tissue expanders from the market to protect patients from breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Smooth surfaced implants are not affected by this recall (FDA, 2021).
- Ideal Implant Saline-Filled Breast Implant (P120011)
- Mentor Saline-Filled and Spectrum® Breast Implants (P990075)

The FDA approved saline-filled breast implants for breast augmentation in women age 18 or older and for breast reconstruction in women of any age. They are also used in revision surgeries, which correct or improve the result of an original surgery.

FDA-approved silicone gel-filled breast implants:

- Allergan Natrelle® Silicone Gel-Filled Breast Implants (P990074 and P020056)
 - In July 2019, Allergan voluntarily recalled Natrelle BIOCELL textured breast implants and tissue expanders from the market to protect patients from BIA-ALCL. Smooth surfaced implants are not affected by this recall (FDA, 2021).
- Allergan Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implant (P040046)
 - In July 2019, Allergan voluntarily recalled Natrelle BIOCELL textured breast implants and tissue expanders from the market to protect patients from BIA-ALCL. Smooth surfaced implants are not affected by this recall (FDA, 2021).
- Mentor MemoryGel® Silicone Gel-Filled Breast Implants (P030053)
- Mentor MemoryShape® Silicone Gel-Filled Breast Implant (P060028)
- Sientra Silicone Gel Breast Implant (P070004)

The FDA labeling for silicone and saline breast implantation states breast implant surgery should not be performed in women with: an active infection, existing cancer or precancer of a breast that has not been adequately treated, or who are pregnant or nursing.

On September 8, 2022, updated Mar 22, 2023, the FDA issued a safety communication about reports of cancers, including squamous cell carcinoma (SCC) and various lymphomas, in the scar tissue (capsule) that forms around breast implants. The various lymphomas are different than the previously reported Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). The safety communication states that the FDA believes the occurrence of SCC or various lymphomas in the capsule are rare, however the incidence rate and risk factors for are unknown. Reported signs

and symptoms included swelling, pain, lumps or skin changes. The FDA does not recommend the removal of breast implants because of this safety communication.

On October 27, 2021, the FDA issued new labeling requirements for all legally marketed breast implants due to ongoing concerns about the possible risk of systemic illness or anaplastic large cell lymphoma in patients with silicone gel-filled breast implants. Additionally, the sale and distribution of breast implants will be restricted only to health care providers and facilities that provide information to patients using the "Patient Decision Checklist." The manufacturers are required to post the following updated device labeling to their websites:

- "Boxed warning.
- Patient decision checklist, which must be reviewed with the prospective patient by the health care provider to help ensure the patient understands the risks, benefits and other information about the breast implant device. The patient must be given the opportunity to initial and sign the patient decision checklist and it must be signed by the physician implanting the device.
- Updated silicone gel-filled breast implant rupture screening recommendations.
- Device description with a list of specific materials in the device.
- Patient device card."

In June 2011 (updated 2018), the FDA released a report updating the clinical and scientific information for silicone gel-filled breast implants, including preliminary safety data from studies conducted by the manufacturers as a condition of their November 2006 approval. The conclusion in the report states that, "Based on the totality of the evidence, the FDA believes that silicone gel-filled breast implants have a reasonable assurance of safety and effectiveness when used as labeled. Despite frequent local complications and adverse outcomes, the benefits and risks of breast implants are sufficiently well understood for women to make informed decisions about their use. Manufacturers and physicians should continue to provide balanced and up-to-date information to women considering breast implants to help inform their decisions" (FDA, 2018).

Implant Rupture and Deflation

Breast implants are not considered lifetime devices. Trauma is a common cause of rupture. Some implants will spontaneously deflate or rupture immediately after implantation; some will deflate over time, while others may remain intact for 10 or more years following surgery.

Silicone Gel-Filled Implant Rupture

Silicone gel-filled implants may rupture as the result of the age of the implant, the presence of a capsular contracture, or trauma. When silicone gel-filled implants rupture, a patient may experience decreased breast size, nodules, asymmetrical appearance of the breasts, pain, tenderness, swelling, tingling or numbness. Other ruptures may be completely asymptomatic (i.e., silent ruptures). Silicone gel that extrudes beyond the reactive fibrotic capsule (i.e., extracapsular rupture) that forms surrounding the implant may migrate away from the breast. The free, migrated silicone may result in the formation of granulomas in the breast or other areas such as the chest wall or axillae. Some granulomas can migrate to lymph nodes in the axillae and may even mimic cancer. Extruded silicone gel that is contained within the fibrotic capsule is referred to as an intracapsular rupture.

MRI may be used to view the prosthesis in the breast and assist in determining if leakage of the materials has occurred. MRI may be medically necessary to confirm suspected silicone gel-filled breast implant rupture when this diagnosis cannot be confirmed by mammography or breast ultrasound.

In 2001 (reviewed 2018), the FDA completed a study on the health effects of ruptured silicone gel breast implants. The goal of this study was to determine if a correlation exists between loose

silicone that migrates into the tissue and the development or progression of collagen vascular disease. A total of 343 women volunteered to participate in this study via a questionnaire concerning joint pain, swelling or stiffness, rash on the breasts and chest, and fatigue. These participants were also questioned about being diagnosed with any illnesses such as scleroderma, fibromyalgia, chronic fatigue syndrome or lupus. All participants underwent MRI to determine if their implants were intact or ruptured with extruded silicone gel. This study concluded that, for women who reported fibromyalgia, MRI did confirm that silicone gel had consistently extruded outside of the fibrous scar.

Saline-Filled Implant Rupture

Saline-filled breast implants may deflate or rupture when saline solution leaks through an unsealed or damaged valve or through a break in the implant shell. Implant deflation may occur in the immediate postoperative period or slowly develop over a period of time. An alteration in the appearance of the breast may result; however, the presence of a ruptured or leaking saline-filled implant does not lead to any medical complications that require intervention, such as removal of the implant. The leakage or rupture of a saline-filled breast implant, in the absence of other signs or symptoms (e.g., significant capsular contracture or persistent infection), is not a medically necessary indication to undergo capsulectomy and breast implant removal.

Periprosthetic Capsular Contracture

When a breast implant is inserted, a scar capsule forms around it as part of the natural healing process. Capsular contracture occurs when the scar tissue or capsule that normally forms around the implant tightens, ultimately squeezing the implant. Significant contracture may result in severe pain or may be associated with subclinical infection. The presence of a contracture may also interfere with the ability to diagnose or treat breast cancer. The degree of periprosthetic contracture is often classified by using the Baker grading system. The four Baker grades are as follows (American Society of Plastic Surgeons [ASPS], 2018):

- **Grade 1:** Grade one capsular contracture is asymptomatic (producing or showing no symptoms). The formation of scar tissue around the implant does not interfere with the size, shape or texture of the breasts. The breasts look natural and remain soft to the touch.
- **Grade 2:** Grade two capsular contracture usually presents itself with only minor cosmetic symptoms. The breasts will usually appear normal in shape but feel somewhat firm to the touch.
- **Grade 3:** Grade three capsular contracture presents itself with obvious cosmetic symptoms. The breasts will be firm to the touch and appear abnormal, e.g., they will be overly round, hard-looking and the nipples may be misshapen. However, this grade of capsular contraction often doesn't cause much (if any) pain.
- **Grade 4:** Like grade three capsular contracture, grade four capsular contracture causes the breasts to become hard and misshapen. Patients with grade four capsular contracture also experience breast soreness; their breasts will often be tender and painful to the touch."

Treatment of clinically significant contractures (i.e., Baker grade IV) can range from removing the capsular tissue (e.g., capsulectomy) to removal of the implant itself. Infections that occur due to the presence of a breast implant rupture and/or capsular contracture are typically treated with antibiotics.

The pathogenesis of fibrous capsular contracture after breast augmentation with implants is still under debate and varies from patient to patient. In a prospective study by Pajkos et al. (2003), biofilm, in particular, *S. epidermidis* biofilm, was found in a significant proportion of patients with capsular contracture. This thin layer of bacteria can develop around the implant(s) after a type of bacteria (e.g. staph bacteria) is introduced to the breast cavity during surgery. Other theories

regarding the development of capsular contracture include genetics, hematomas and seromas (ASPS, 2018).

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Individuals with breast implants have a risk of developing breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). BIA-ALCL is not breast cancer rather it is a rare type of non-Hodgkin's lymphoma (cancer of the immune system). Symptoms are persistent swelling, presence of a mass or pain in the area of the breast implant. These symptoms can occur years after the implantation. In most cases, BIA-ALCL is found in the fluid surrounding the implant (seroma) or contained within the fibrous scar capsule, but in some cases, it can spread throughout the body. BIA-ALCL is diagnosed by pathology/cytology testing of the seroma fluid or mass, with Wright Giemsa stained smears and cell block immunohistochemistry/flow cytometry testing for cluster of differentiation (CD30) and Anaplastic Lymphoma Kinase (ALK) markers. Precise risks are difficult to determine due to lack of information about how many patients have received breast implants in the U.S. and worldwide (FDA, 2019).

FDA recommendations state that BIA-ALCL has generally only been identified in patients with symptoms such as pain, lumps, persistent swelling, or breast asymmetry that occur years after implantation. Implant removal in patients without signs or symptoms for prophylactic reasons is not recommended. The FDA recommends reporting all BIA-ALCL cases to MedWatch, the FDA Safety Information and Adverse Event Reporting program and case reports to the PROFILE Registry. The PROFILE Registry was developed in 2012. On July 24, 2019, the FDA requested that Allergan, the manufacturer of a specific type of textured implant, recall specific models of its textured breast implants from the U.S. market due to the risk of BIA-ALCL. The FDA's analysis in 2019 was attributed to a worldwide reported total of 573 unique BIA-ALCL cases including 33 patient deaths. Of the 573 cases of BIA-ALCL, 481 are reported to have Allergan breast implants at the time of diagnosis. (FDA, 2019; FDA, 2019). As of April 1, 2022, there have been 1,130 unique BIA-ALCL cases combined in the United States and globally with 59 deaths (FDA, 2022).

The National Comprehensive Cancer Network® (NCCN) Clinical Guidelines in Oncology™ T Cell Lymphomas addresses BIA-ALCL. The NCCN reports that in recent years the instances of BIA-ALCL has increased. Initial workup for BIA-ALCL includes ultrasound of the breast and axilla or breast MRI in selected cases or PET/CT scan in selected cases. If ultrasound is inconclusive, breast MRI is recommended. Cytology with cell block preparation and flow cytometry immunophenotype are essential to confirm the diagnosis of BIA-ALCL. A biopsy is useful if there is a solid mass associated with the implant. Referral to a plastic surgeon for management of an implant seroma is recommended if the pathologic diagnosis is negative for lymphoma. A second pathology consultation is recommended in a tertiary cancer center if the pathologic diagnosis is indeterminate of lymphoma. Individualized management by a multidisciplinary team is recommended for histologically confirmed BIA-ALCL. The NCCN treatment recommendations for patients with BIA-ALCL include total capsulectomy with removal of the breast implant and excision of any associated mass with a biopsy of suspicious lymph nodes for all patients (NCCN, 2023).

According to the American Society of Plastic Surgeons (ASPS) statement titled "Insurance coverage criteria for third party payers - BIA-ALCL", anaplastic large cell lymphoma (ALCL) is a rare type of cancer of the immune system that is estimated to affect 1 in half a million women. BIA-ALCL is a rare lymphoma, and is not a breast cancer. Most women approach their doctor with symptoms such as pain, lumps, swelling, regional lymphadenopathy, or asymmetry in their breasts years after getting implants. BIA-ALCL has been estimated to affect 1 in 1,000 to 1 in 30,000 women with textured breast implants. In patients without symptoms or other abnormalities, the FDA does not recommend screening tests or prophylactic breast implant removal. The ASPS policy follows the NCCN clinical guideline treatment recommendations for BIA-ALCL (ASPS, 2020).

Kim et al. (2011) conducted a systematic literature review to identify and analyze all reported cases of non-Hodgkin's lymphoma occurring in patients with breast implants. The total number of articles included in the analysis was 34 which included 36 cases of ALCL and other non-Hodgkin's lymphomas involving the breast: 29 (81%) were ALCL. Although detailed clinical information was lacking in many cases, ALCL often involved the capsule and/or presented as an unexplained seroma or mass, was negative for anaplastic lymphoma kinase (ALK) expression, and had a relatively indolent clinical course when it developed adjacent to a breast implant. The authors concluded that a form of ALCL, which clinically behaves more like the less aggressive primary cutaneous form of ALK-negative ALCL rather than the more aggressive systemic form, may be associated with breast implants.

Autoimmune Diseases, Connective Tissue Diseases, Breast Cancer and the Presence of Intact Breast Implants

In the early 1980s, reports suggested an association between silicone breast implants and various connective tissue diseases, but only limited analytic epidemiological data addressing this hypothesis were available at the time. As a consequence, in 1992, the FDA banned the use of silicone breast implants, restricting them to breast cancer reconstructive surgery in a strictly controlled clinical trial. In November 2006, after further scientific review, the FDA lifted their ban on silicone breast implants, approving the use of silicone implants for breast reconstruction for women of any age and for breast augmentation for women age 22 years or older.

The American Academy of Neurology, the American College of Surgeons, the American College of Rheumatology, the American Medical Association, the American Society of Plastic Surgeons and the American Society of Clinical Oncology all agree with the findings of a 2000 study of 13,500 women researched by the National Cancer Institute. This study found no correlation between breast implants and the development of connective or autoimmune disease or an increase in breast cancer risk (Nelson, 2000).

McLaughlin et al. (2007) summarized the epidemiologic evidence regarding the safety of silicone gel-filled breast implants. The topics included in this report included CTD, suicide, offspring effects, neurologic disease, implant rupture, and local perioperative complications requiring the need for additional surgery. Based on the review of the published epidemiologic literature on the safety of breast implants, through September 2007, the authors reported that "the weight of the epidemiologic evidence does not support a causal association between breast implants and breast or any other type of cancer, definite or atypical connective tissue disease, adverse offspring effects, or neurologic disease. Women with breast implants do not present with more advanced stages of breast cancer or suffer impaired survival after breast cancer diagnosis. The only study to examine an actual incidence rate of breast implant rupture reported rupture-free survival of 98% at five years and 83%–85% at 10 years for newer "third-generation" implants. Future studies are needed to determine whether the consistently observed excess of suicide among women with implants reflects underlying psychiatric illness prior to breast augmentation surgery or other factors."

A review of epidemiological evidence by Lipworth et al. (2004) concluded that the most recent epidemiological investigations have been remarkably consistent with earlier epidemiological studies in finding no evidence of an excess of any individual CTD or all CTDs combined, including both established and atypical or undefined CTD, among women with cosmetic silicone breast implants.

Implant Shifting

Some implants may shift or move over time while remaining intact. Aside from the potential for an untoward cosmetic appearance, implant shifting does not lead to any medical complications that

require intervention, such as removal of the implant. Implant shifting, in the absence of other signs or symptoms such as significant capsular contracture, persistent infection, or rupture of a silicone gel-filled implant, is not a medically necessary indication to remove.

Medicare Coverage Determinations

	Contractor	Determination Name/Number	Revision Effective Date
NCD		No National Determination found	
LCD	Palmetto GBA	Cosmetic and Reconstructive Surgery (L33428)	7/29/2021
LCD	Novitas Solutions, Inc.	Cosmetic and Reconstructive Surgery (L35090)	7/11/2021

Note: Please review the current Medicare Policy for the most up-to-date information. (NCD = National Coverage Determination; LCD = Local Coverage Determination)

Coding Information

Notes:

1. This list of codes may not be all-inclusive since the American Medical Association (AMA) and Centers for Medicare & Medicaid Services (CMS) code updates may occur more frequently than policy updates.
2. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Implant Removal Associated with Breast Reconstruction or Lumpectomy

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT®* Codes	Description
19328 [†]	Removal of intact breast implant
19330	Removal of ruptured breast implant, including implant contents (eg, saline, silicone gel)
19370	Revision of peri-implant capsule, breast, including capsulotomy, capsulorrhaphy, and/or partial capsulectomy
19371	Peri-implant capsulectomy, breast, complete, including removal of all intracapsular contents

†Note: Considered Not Medically Necessary when removal of an intact silicone gel-filled breast implant is performed solely for suspected autoimmune disease, connective tissue disease or for breast cancer prevention.

Rupture of Gel-Filled Implant

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT®* Codes	Description
19330	Removal of ruptured breast implant, including implant contents (eg, saline, silicone gel)
19370	Revision of peri-implant capsule, breast, including capsulotomy, capsulorrhaphy, and/or partial capsulectomy
19371	Peri-implant capsulectomy, breast, complete, including removal of all intracapsular contents

Interference with Diagnostic Evaluation or Treatment

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT®* Codes	Description
19328	Removal of intact breast implant
19330	Removal of ruptured breast implant, including implant contents (eg, saline, silicone gel)
19370	Revision of peri-implant capsule, breast, including capsulotomy, capsulorrhaphy, and/or partial capsulectomy
19371	Peri-implant capsulectomy, breast, complete, including removal of all intracapsular contents

Infection, Contracture, Tissue Necrosis

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT®* Codes	Description
19328	Removal of intact breast implant
19330	Removal of ruptured breast implant, including implant contents (eg, saline, silicone gel)
19370	Revision of peri-implant capsule, breast, including capsulotomy, capsulorrhaphy, and/or partial capsulectomy
19371	Peri-implant capsulectomy, breast, complete, including removal of all intracapsular contents

***Current Procedural Terminology (CPT®) ©2023 American Medical Association: Chicago, IL.**

References

1. Aladily TN, Medeiros LJ, Amin MB, Haideri N, Ye D, Azevedo SJ, et al. Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. Am J Surg Pathol. 2012 Jul;36(7):1000-8. .
2. American Society of Plastic Surgeons (ASPS). BIA-ALCL Resources. Last updated 2022. Accessed Nov 17, 2023. Available at URL address: <https://www.plasticsurgery.org/patient-safety/breast-implant-safety/bia-alcl-summary/frequently-asked-questions>

3. American Society of Plastic Surgeons (ASPS). ASPS Recommended Insurance Coverage for Third Party Payers. Breast Implant Associated Anaplastic Large Cell Lymphoma. Approved Oct 2017; Reapproved Jun 2020. Accessed Nov 17, 2023. Available at URL address: <https://www.plasticsurgery.org/documents/Health-Policy/Reimbursement/Insurance-2017-BIA-ALCL.pdf>
4. American Society of Plastic Surgeons (ASPS). What is capsular contracture and how can it be treated? Jun 12, 2018. Accessed Nov 17, 2023. Available at URL address: <https://www.plasticsurgery.org/news/blog/what-is-capsular-contracture-and-how-can-it-be-treated/>
5. Brinton LA, Buckley LM, Dvorkina O, Lubin JH, Colton T, Murray MC, et al. Risk of connective tissue disorders among breast implant patients. *Am J Epidemiol*. 2004 Oct 1;160(7):619-27.
6. Centers for Medicare and Medicaid Services (CMS). Local Coverage Determinations (LCDs) alphabetical index. Accessed Dec 4, 2023. Available at URL address: <https://www.cms.gov/medicare-coverage-database/search.aspx>
7. Centers for Medicare and Medicaid Services (CMS). National Coverage Determinations (NCDs) alphabetical index. Accessed Dec 4, 2023. Available at URL address: <https://www.cms.gov/medicare-coverage-database/search.aspx>
8. Coroneos CJ1, Selber JC, Offodile AC 2nd, Butler CE, Clemens MW. US FDA breast implant postapproval studies: Long-term outcomes in 99,993 patients. *Ann Surg*. 2019 Jan;269(1):30-36. doi: 10.1097/SLA.0000000000002990
9. Chun JK, Schulman MR. The infected breast prosthesis after mastectomy reconstruction: successful salvage of nine implants in eight consecutive patients. *Plast Reconstr Surg*. 2007 Sep;120(3):581-9.
10. Clemens MW, Jacobsen E. Breast implant-associated anaplastic large cell lymphoma. In: UpToDate, Collins, K(Ed), UpToDate, Jun 13, 2023. Waltham, MA. Accessed on Nov 17, 2023.
11. Clemens MW, Horwitz SM. NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma. *Aesthet Surg J*. 2017 Mar 1;37(3):285-289.
12. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, et al. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. *J Clin Oncol*. 2016 Jan 10;34(2):160-8. doi: 10.1200/JCO.2015.63.3412. Epub 2015 Nov 30. Erratum in: *J Clin Oncol*. 2016 Mar 10;34(8):888.
13. DeJong WH, Kallewaard M, Goldhoorn, CA, Verhoef CM, Bijlsma J, Schouten J, et al. Long term exposure to silicone breast implants does not induce antipolymer antibodies. *Biomaterials*. 2004 Mar;25(6):1095-103.
14. Fryzek JP, Signorello LB, Hakelius L, Lipworth L, McLaughlin JK. Local complications and subsequent reporting among women with cosmetic breast implants. *Plast Reconstr Surg*. 2001 Jan;107(1):214-21.

15. Gampper TJ, Khoury H, Gottlieb W, Morgan RF. Silicone gel implants in breast augmentation and reconstruction. *Ann Plast Surg.* 2007 Nov;59(5):581-90.
16. Gidengil CA, Predmore Z, Mattke S, van Busum K, Kim B. Breast implant-associated anaplastic large cell lymphoma: a systematic review. *Plast Reconstr Surg.* 2015 Mar;135(3):713-20.
17. Henriksen TF, Fryzek JP, Holmich LR, McLaughlin JK, Kjoller K, Hoyer AP, Olsen JH, Friis S. Surgical intervention and capsular contracture after breast augmentation: a prospective study of risk factors. *Ann Plast Surg.* 2005 Apr;54(4):343-51.
18. Holmich LR, Fryzek JP, Kjoller K, Breiting VB, Jorgensen A, Krag C, McLaughlin JK. The diagnosis of silicone breast-implant rupture: clinical findings compared with findings at magnetic resonance imaging. *Ann Plast Surg.* 2005 Jun;54(6):583-9.
19. Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the relation between silicone breast implants and the risk of connective tissue diseases. *N Engl J Med.* 2000;342:781-90.
20. Kim M, Ku I, Jin US. Diagnosis and management of toxic shock syndrome after breast reconstructive procedures with silicone implants. *Arch Plast Surg.* 2021 Mar;48(2):189-193. doi: 10.5999/aps.2020.01144. Epub 2021 Mar 15. PMID: 33765737; PMCID: PMC8007467.
21. Kim B, Roth C, Chung KC, Young VL, van Busum K, Schnyer C, Mattke S. Anaplastic large cell lymphoma and breast implants: a systematic review. *Plast Reconstr Surg.* 2011 Jun;127(6):2141-50.
22. Kim B, Predmore ZS, Mattke S, van Busum K, Gidengil CA. Breast Implant-associated Anaplastic Large Cell Lymphoma: Updated Results from a Structured Expert Consultation Process. *Plast Reconstr Surg Glob Open.* 2015 Feb 6;3(1):e296. doi: 10.1097/GOX.0000000000000268. eCollection 2015 Jan.
23. Lalani T, Zenn M. Breast Implant Infections. In: UpToDate, Hall, KK, Ed. UpToDate, Oct 5, 2022. Waltham, MA. Accessed on Nov 13, 2023.
24. Leberfinger AN, Behar BJ, Williams NC, Rakszawski KL, Potochny JD, Mackay DR, Ravnic DJ. Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review. *JAMA Surg.* 2017 Dec 1;152(12):1161-1168.
25. Lipworth L, Tarone RE, McLaughlin JK. Breast implants and fibromyalgia. a review of the epidemiologic evidence. *Ann Plast Surg.* 2004 March;52(3):284-7.
26. Lipworth L, Tarone RE, McLaughlin JK. Silicone breast implants and connective tissue disease: an updated review of the epidemiologic evidence. 2004 Jun;52(6):598-601.
27. Loch-Wilkinson A, Beath KJ, Knight RJW, Wessels WLF, Magnusson M, Papadopoulos T, et al. Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk. *Plast Reconstr Surg.* 2017 Oct;140(4):645-654.
28. McLaughlin JK, Lipworth L, Murphy DK, Walker PS. The safety of silicone gel-filled breast implants: a review of the epidemiologic evidence. *Ann Plast Surg.* 2007 Nov;59(5):569-80.

29. Nahabedian M. Complications of reconstructive and aesthetic breast surgery. In: UpToDate, Collins, KA, Ed. UpToDate, Apr 12, 2023. Waltham, MA. Accessed on Nov 17, 2023.
30. Nahabedian M. Implant-based breast reconstruction and augmentation. In: UpToDate, Collins, KA, Ed. UpToDate, Mar 15, 2023. Waltham, MA. Accessed on Nov 17, 2023.
31. National Comprehensive Cancer Network® (NCCN). NCCN GUIDELINES™ Clinical Guidelines in Oncology™. T Cell Lymphomas. V 1.2023. Jan 5, 2023. © National Comprehensive Cancer Network, Inc., 2022. All Rights Reserved. Accessed Nov 13, 2023. Available at URL address: https://www.nccn.org/professionals/physician_gls/default.aspx
32. National Cancer Institute. Breast Reconstruction After Mastectomy. Reviewed February 24, 2017. Accessed Nov 17, 2023. Available at URL address: <http://www.cancer.gov/types/breast/reconstruction-fact-sheet>
33. Nelson NJ. Silicone breast implants not linked to breast cancer risk. J Natl Cancer Inst. 2000 Nov 1;92(21):1714-5. doi: 10.1093/jnci/92.21.1714. PMID: 11058613.
34. Nyren O, Yin L, Joseffson S, McLaughlin JK, Blot WJ, Engqvist M, et al. Risk of connective tissue disease and related disorders among women with breast implants: a nation-wide retrospective cohort study in Sweden. BMJ. 1998 Feb 7;316(7129):417-22.
35. O'Hanlon T, Bhanu K, Elham B, Love L, Targoff I, Malley J, et al. Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. Arthritis Rheum. 2004 Nov;50(11):3646-50.
36. Pajkos A, Deva AK, Vickery K, Cope C, Chang L, Cossart YE. Detection of subclinical infection in significant breast implant capsules. Plast Reconstr Surg. 2003 Apr 15;111(5):1605-11.
37. Pittet B, Montandon D, Pittet D. Infection in breast implants. Lancet Infect Dis. 2005 Feb;5(2):94-106.
38. Plastic Surgery Foundation. PROFILE (Patient Registry and Outcomes For breast Implants and anaplastic large cell Lymphoma etiology and Epidemiology) Registry. 2023. Accessed Nov 17, 2023. Available at URL address: <https://www.thepsf.org/research/registries/profile>
39. Sampedro MF, Patel R. Infections associated with long-term prosthetic devices. Infect Dis Clin North Am. 2007 Sep;21(3):785-819, x.
40. Scaranelo AM, Marques AF, Smialowski EB, Lederman HM. Evaluation of the rupture of silicone breast implants by mammography, ultrasonography and magnetic resonance imaging in asymptomatic patients: correlation with surgical findings. Sao Paulo Med J. 2004 Mar 4;122(2):41-7.
41. Seify H, Sullivan K, Hester TR. Preliminary (3 years) experience with smooth wall silicone gel implants for primary breast augmentation. Ann Plast Surg. 2005 Mar;54(3):231-5; discussion 235.
42. Song JW, Kim HM, Bellfi LT, Chung KC. The effect of study design biases on the diagnostic accuracy of magnetic resonance imaging for detecting silicone breast implant ruptures: a meta-analysis. Plast Reconstr Surg. 2011 Mar;127(3):1029-44.

43. Stevens WG, Calobrace MB, Alizadeh K, Zeidler KR, Harrington JL, d'Incelli RC. Ten-year Core Study Data for Sientra's Food and Drug Administration-Approved Round and Shaped Breast Implants with Cohesive Silicone Gel. *Plast Reconstr Surg.* 2018 Apr;141(4S Sientra Shaped and Round Cohesive Gel Implants):7S-19S.
44. The Aesthetic Society. Breast Augmentation. 2009-2023. Accessed Nov 17, 2023. Available at URL address: <http://www.smartbeautyguide.com/procedures/breast/breast-augmentation>
45. U.S. Food and Drug Administration (FDA). Breast Implants. Page last updated: Mar 8, 2023. Accessed Nov 17, 2023. Available at URL address: <https://www.fda.gov/medical-devices/implants-and-prosthetics/breast-implants>
46. U.S. Food and Drug Administration (FDA). Center for Devices and Radiological Health. Mentor Corporation Saline-filled and Spectrum® Breast Implants (P990075). Issued May 10, 2000. Accessed Nov 14, 2023. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>
47. U.S. Food and Drug Administration (FDA). Center for Devices and Radiological Health. Ideal Implant® Saline-filled Breast Implant (P120011). Issued Nov 14, 2014. Accessed Nov 14, 2023. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>
48. U.S. Food and Drug Administration (FDA). Center for Devices and Radiological Health. Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-filled Breast Implant. (P040046). Issued Feb 20, 2013. Accessed Nov 14, 2023. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>
49. U.S. Food and Drug Administration (FDA). Center for Devices and Radiological Health. MemoryShape Breast Implants (P060028). Issued Jun 14, 2013. Accessed Nov 14, 2023. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>
50. U.S. Food and Drug Administration (FDA). Center for Devices and Radiological Health. Mentor MemoryGel™ Silicone Gel-filled Breast Implants (P030053). Issued Nov 17, 2006. Accessed Nov 14, 2023. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>
51. U.S. Food and Drug Administration (FDA). Center for Devices and Radiological Health. Allergan Natrelle saline-filled breast implants (P020056). Issued Nov 17, 2006. Accessed Nov 14, 2023. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>
52. U.S. Food and Drug Administration (FDA). Center for Devices and Radiological Health. Allergan Natrelle Silicone-Filled Breast Implants (P990074). Issued May 10, 2000. Accessed Nov 14, 2023. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>
53. U.S. Food and Drug Administration (FDA). Center for Devices and Radiological Health. Sientra Silicone Gel-Filled Breast Implants (P070004). Issued Mar 9, 2012. Accessed Nov 14, 2023. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>

54. U.S. Food and Drug Administration (FDA). FDA news release: FDA takes action to protect patients from risk of certain textured breast implants; requests Allergan voluntarily recall certain breast implants and tissue expanders from market. Content current as of July 24, 2019. Accessed Nov 14, 2023. Available at URL address: <https://www.fda.gov/news-events/press-announcements/fda-takes-action-protect-patients-risk-certain-textured-breast-implants-requests-allergan>
55. U.S. Food and Drug Administration (FDA). Labeling for approved breast implants. Page last updated: Aug 4, 2022. Accessed Nov 14, 2023. Available at URL address: <https://www.fda.gov/medical-devices/breast-implants/labeling-approved-breast-implants>
56. U.S. Food and Drug Administration (FDA). Medical device reports of breast implant-associated anaplastic large cell lymphoma. Page last updated Aug 4, 2022. Accessed Nov 17, 2023. Available at URL address: <https://www.fda.gov/medical-devices/breast-implants/medical-device-reports-breast-implant-associated-anaplastic-large-cell-lymphoma>
57. U.S. Food and Drug Administration (FDA). Questions and answers about breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Page last updated Oct 23, 2019. Accessed Nov 17, 2023. Available at URL address: <https://www.fda.gov/medical-devices/breast-implants/questions-and-answers-about-breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl>
58. U.S. Food and Drug Administration (FDA). Reports of anaplastic large cell lymphoma (ALCL) in women with breast implants: FDA safety communication. Date issued Jan 26, 2011. Page last updated Jan 15, 2016. Accessed Nov 17, 2023. Available at URL address: <http://wayback.archive-it.org/7993/20170111070030/http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm240000.htm>
59. U.S. Food and Drug Administration (FDA). Risks and complications of breast implants. Page last updated Mar 8, 2023. Accessed Nov 17, 2023. Available at URL address: <https://www.fda.gov/medical-devices/breast-implants/risks-and-complications-breast-implants>
60. U.S. Food and Drug Administration (FDA). Saline, Silicone Gel, and Alternative Breast Implants. Guidance for Industry and FDA Staff. Page last updated Sept 28, 2020. Accessed Nov 17, 2023. Available at URL address: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/saline-silicone-gel-and-alternative-breast-implants>
61. U.S. Food and Drug Administration (FDA). Safety Communication. Breast implants: Reports of squamous cell carcinoma and various lymphomas in capsule around implants: FDA Safety Communication. Sep 8, 2022, updated Mar 22, 2023. Accessed on Nov 14, 2023. Available at URL address: <https://www.fda.gov/medical-devices/safety-communications/breast-implants-reports-squamous-cell-carcinoma-and-various-lymphomas-capsule-around-implants-fda>
62. U.S. Food and Drug Administration (FDA). Study of silicone gel breast implant rupture, extracapsular silicone, and health status in a population of women. May 29, 2001. Page last updated Jan 18, 2018. Accessed Nov 17, 2023. Available at URL address: <http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm064382.htm>

- 63. U.S. Food and Drug Administration (FDA). Types of breast implants. Page last updated: Oct 23, 2019. Accessed Nov 17, 2023. Available at URL address: <https://www.fda.gov/medical-devices/breast-implants/types-breast-implants>
- 64. U.S. Food and Drug Administration (FDA). Update on the safety of silicone gel-filled breast implants (2011) - Executive Summary. Page last updated Jul 16, 2018. Accessed Nov 17, 2023. Available at URL address: <https://www.fda.gov/medical-devices/breast-implants/update-safety-silicone-gel-filled-breast-implants-2011-executive-summary>

Revision Details

Type of Revision	Summary of Changes	Date
Annual review	<ul style="list-style-type: none"> • No changes to policy statement 	1/15/2024

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.